 |
|
|
Wed, Mar 10, 2010According to the latest meta-analysis, erythropoiesis-stimulating agents (ESAs) showed no significant effect on survival, ...
More
The Network for Advancement of Transfusion Alternatives (NATA) is hosting its 11th Annual two-day conference on April 8 and ...
More
The European Hematology Association is hosting a scientific workshop in Cascais, Portugal, on April 15-18, 2010 to discuss ...
More
The stimulation of neutralizing antierythropoietin antibodies is a rare complication of recombinant human erythropoietin use ...
More
The data from this pivotal study, lead Pfeffer, et al., to conclude that: “for many persons involved in clinical decision ...
More
See all news items >> |
|
|
 |
|
|
|
 |
|
|
|
|
Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
Shander A, Spence RK, Auerbach M
Transfusion. 2009 Nov 16. [Epub ahead of print]
For over 20 years now, erythropoietic stimulating agents (ESA) have been administered to millions of patients with relatively few side-effects. In more recent years, however, a number of studies have raised concerns about the possibility of ESAs’ playing a causative role in thrombotic events and more rapid tumor progression in some cancers. For ...
...
Full article >> |
|
|
|
|
|
|
March 10, 2009
Wish to comment on the new Textbook?
Click
here >> |
|
|
|
|
|
|
|
|
|
|
|
|
April 8 to 9, 2010Barcelona, Spain11th Annual Network for the Advancement of Transfusion Alternatives - NATA
April 15 to 18, 2010Cascais, PortugalESH-EHA Scientific Workshop-Innovative Therapies For Red Cell And Iron Related Disorders
May 25 to 28, 2010Lausanne, SwitzerlandXV International Congress on Nutrition and Metabolism in Renal Disease
June 2 to 5, 2010Cairns, AustraliaRenal Society of Australia 2010
View all upcoming
events >>
|
|
|
|
|
